From Free Rider to Innovator: The Rise of China's Drug Development | NBER

Founded in 1920, the NBER is a private, non-profit, non-partisan organization dedicated to conducting economic research and to disseminating research findings among academics, public policy makers, and business professionals.

From Free Rider to Innovator: The Rise of China's Drug Development | NBER Skip to main content From Free Rider to Innovator: The Rise of China's Drug Development Panle Jia Barwick , Hongyuan Xia & Tianli Xia Share X LinkedIn Facebook Bluesky Threads Email Link Working Paper 34977 DOI 10.3386/w34977 Issue Date March 2026 This paper examines China’s transition from pharmaceutical “free rider” to global innovator over the last decade. In 2010, China accounted for less than 8% of global clinical trials; by 2020, it had surpassed the US in annual registered clinical trial volume. To study

related reading

• Old Space, New Space: A Commercial Revolution in Innovation?nber.org
• Home | Levers for Progressleversforprogress.com
• AI Patents in the United States and China: Measurement, Organization, and Knowledge Flowsnber.org
• The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
• Where are all the trillion dollar biotechs?ladanuzhna.xyz
• Life and Growth | NBERnber.org
• Reluctant Entrepreneurs: Evidence from China’s SOE Reform | NBERnber.org
• The rise and fall of the industrial R&D lab - Works in Progress Magazineworksinprogress.co
• Premature Deindustrializationnber.org
• Unblock research bottlenecks with non-profit start-upsnature.com
• Overcoming India's technological cowardiceinfinitesunrise.com
• Incentives and Prosocial Discomfort: A Laboratory Experiment | NBERnber.org